Related Experiment Video
Updated: Nov 14, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Anticancer effect of sodium metavanadate on murine breast cancer both in vitro and in vivo
Abstract:
Sodium metavanadate (NaVO3) exhibits important physiological effects including insulin-like, chemoprevention and anticancer activity. However, the effects of NaVO3 on breast cancer and underlying mechanisms are still unclear. In this study, our results revealed that NaVO3 was able to inhibit proliferation of murine breast cancer cells 4T1 with IC50 value of 8.19 μM and 1.92 μM at 24 h and 48 h, respectively. The mechanisms underlying the inhibition activity were that NaVO3 could increase reactive oxygen species (ROS) level in a concentration-dependent way, arrest cells at G2/M phase, diminish the mitochondrial membrane potential (MMP), finally promote the progress of apoptosis. Furthermore, NaVO3 also exhibited a dose-dependent anticancer activity in breast cancer-bearing mice that led to the shrinkage of tumor volume (about 50%), lower microvessel density, less propagating cells and more apoptotic cells in vivo, as compared to the saline group. Therefore, NaVO3 may act as a potential chemotherapeutic agent in breast cancer treatment.
Insights
Sodium metavanadate (NaVO3) effectively inhibits breast cancer cell proliferation and tumor growth in mice. This compound induces apoptosis and reduces tumor vascularity, suggesting its potential as a breast cancer therapeutic agent.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Sodium metavanadate (NaVO3) shows promise for chemoprevention and anticancer effects.
- The specific impact and mechanisms of NaVO3 on breast cancer remain largely uninvestigated.
Purpose of the Study:
- To investigate the efficacy of sodium metavanadate (NaVO3) against murine breast cancer.
- To elucidate the underlying cellular and molecular mechanisms of NaVO3's anticancer activity.
Main Methods:
- In vitro studies using 4T1 murine breast cancer cells to determine IC50 values.
- Analysis of reactive oxygen species (ROS) levels, cell cycle progression (G2/M arrest), and mitochondrial membrane potential (MMP).
- In vivo studies in breast cancer-bearing mice to evaluate tumor volume, microvessel density, cell proliferation, and apoptosis.
Main Results:
- NaVO3 inhibited 4T1 cell proliferation with IC50 values of 8.19 μM (24h) and 1.92 μM (48h).
- NaVO3 treatment led to increased ROS, G2/M cell cycle arrest, diminished MMP, and induced apoptosis in vitro.
- In vivo, NaVO3 significantly reduced tumor volume by approximately 50%, decreased microvessel density, and increased apoptosis in tumor tissues.
Conclusions:
- Sodium metavanadate demonstrates significant anti-proliferative and pro-apoptotic effects on breast cancer cells.
- NaVO3 exhibits dose-dependent anticancer activity in vivo, reducing tumor growth and associated markers.
- NaVO3 holds potential as a chemotherapeutic agent for breast cancer treatment.
